Prolonged Treatment Response to Pembrolizumab in a Patient with Pretreated Metastatic Colon Cancer and Lynch Syndrome
Pembrolizumab and other immunotherapies now play a prominent role in the treatment of metastatic colon cancer. Clinicians have achieved significant response rates even in heavily pretreated patients, particularly those with mismatched repair deficiencies. The endpoint of pembrolizumab treatment for...
Saved in:
| Main Authors: | Matthew Keating, Lisa Giscombe, Toufic Tannous, Kevan Hartshorn |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2019/3847672 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An Excellent Clinical and Radiological Response Pattern to Pembrolizumab in a Patient With Metastatic Adrenocortical Carcinoma and Lynch Syndrome
by: Yuki Shimozawa, et al.
Published: (2025-07-01) -
P113: Factors associated with precancerous colon polyps (adenomas) in Lynch syndrome patients
by: Rohan Patel, et al.
Published: (2025-01-01) -
Cytokine Release Syndrome Induced by Pembrolizumab for Metastatic Anal Melanoma
by: Erica Martel, et al.
Published: (2025-01-01) -
Lynch Syndrome Associated Colon Adenocarcinoma Resembling Lymphoma on Fluoro-Deoxyglucose-Positron Emission Tomography/Computed Tomography
by: Carina Aparici, et al.
Published: (2015-07-01) -
Cascade genetic testing in Lynch syndrome families
by: Lidija Praprotnik, et al.
Published: (2024-12-01)